Mucosal vaccines: Recent progress in understanding the natural barriers

Pharmaceutical Research

Volumn 27, Issue 2, 2010, Pages 211-223

  Borges, Olga ^a   Lebre, Filipa ^a   Bento, Dulce ^a   Borchard, Gerrit ^b   Junginger, Hans E ^c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c NARESUAN UNIVERSITY   (Thailand)

Author keywords

Adjuvants; Immunoglobulin A; Mucosal immune system; Mucosal vaccines

Indexed keywords

HEPATITIS B VACCINE; IMMUNOGLOBULIN A;

DRUG DELIVERY SYSTEM; HISTORY OF MEDICINE; HUMAN; IMMUNE RESPONSE; IMMUNOPOTENTIATION; INTESTINE LYMPHATIC TISSUE; MUCOSAL IMMUNITY; NASOPHARYNX; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; IMMUNITY, MUCOSAL; MUCOUS MEMBRANE; PRACTICE GUIDELINES AS TOPIC; VACCINES;

EID: 77949272140     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-009-0011-3     Document Type: Review

References (126)

1. MR Hilleman 2000 Vaccines in historic evolution and perspective: a narrative of vaccine discoveries Vaccine 18 15 1436 47 1:STN:280: DC%2BD3c%2Foslejsg%3D%3D 10618541
2. Goldsby RA. Immunology. 5th ed. New York: W.H. Freeman; 2003.
3. S Mitragotri 2005 Immunization without needles Nat Rev Immunol 5 12 905 16 1:CAS:528:DC%2BD2MXht1KntrzK 16239901
4. Mahoney F, Kane M. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: W.B. Saunders Co.; 1999. p. 158-82.
5. MR Hilleman 1987 Yeast recombinant hepatitis B vaccine Infection 15 1 3 7 1:STN:280:DyaL2s7ptlWktg%3D%3D 2437037
6. MR Hilleman 2001 Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications Vaccine 19 15-16 1837 48 1:CAS:528:DC%2BD3MXhsVKlsbs%3D 11228353
7. MR Hilleman R Ellis 1986 Vaccines made from recombinant yeast cells Vaccine 4 2 75 6 1:CAS:528:DyaL28XksVSmurw%3D 3014772
8. S Krugman JP Giles 1973 Viral hepatitis, type B (MS-2-strain). Further observations on natural history and prevention N Engl J Med 288 15 755 60 1:STN:280:DyaE3s7islOnsw%3D%3D 4688714
9. A Budkowska JW Shih JL Gerin 1977 Immunochemistry and polypeptide composition of hepatitis B core antigen (HBc Ag) J Immunol 118 4 1300 5 1:CAS:528:DyaE2sXktVert7Y%3D 66286
10. VA Stewart SM McGrath DS Walsh S Davis AS Hess LA Ware, et al. 2006 Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS, S/AS02A Vaccine 24 42-43 6483 92 1:CAS:528:DC%2BD28XhtVGisbnN 16904798
11. JW Shih JL Gerin 1977 Proteins of hepatitis B surface antigen J Virol 21 1 347 57 1:CAS:528:DyaE2sXkvVaqtb0%3D 833927
12. JW Shih JL Gerin 1977 Proteins of hepatitis B surface antigen: amino acid compositions of the major polypeptides J Virol 21 3 1219 22 1:CAS:528:DyaE2sXkvVaqurs%3D 850309
13. J Stephenne 1988 Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness Vaccine 6 4 299 303 1:STN:280:DyaL1M%2Fks1Sjtw%3D%3D 2973187
14. Stephenne J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine 1990;8 Suppl S69-73: discussion S79-80.
15. P Van Damme M Cramm A Safary P Vandepapeliere A Meheus 1992 Heat stability of a recombinant DNA hepatitis B vaccine Vaccine 10 6 366 7 1534639
16. J Holmgren C Czerkinsky 2005 Mucosal immunity and vaccines Nat Med 11 4 Suppl S45 53 1:CAS:528:DC%2BD2MXjsFWmsro%3D 15812489
17. MR Neutra PA Kozlowski 2006 Mucosal vaccines: the promise and the challenge Nat Rev Immunol 6 2 148 58 1:CAS:528:DC%2BD28XhsFeqtbg%3D 16491139
18. C Czerkinsky SJ Prince SM Michalek S Jackson MW Russell Z Moldoveanu, et al. 1987 IgA antibody-producing cells in peripheral blood after antigen ingestion: evidence for a common mucosal immune system in humans Proc Natl Acad Sci U S A 84 8 2449 53 1:STN:280:DyaL2s7nsFKqsw%3D%3D 3470804
19. MR McDermott J Bienenstock 1979 Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues J Immunol 122 5 1892 8 1:CAS:528:DyaE1MXktlOguro%3D 448111
20. JX Wu J Tai SC Cheung WJ Tze 1997 Assessment of the protective effect of uncoated alginate microspheres Transplant Proc 29 4 2146 7 1:STN:280: DyaK2szjs1yitA%3D%3D 9193563
21. H Kiyono S Fukuyama 2004 NALT- versus Peyer's-patch-mediated mucosal immunity Nat Rev Immunol 4 9 699 710 1:CAS:528:DC%2BD2cXntFCmtL0%3D 15343369
22. EJ Kunkel EC Butcher 2003 Plasma-cell homing Nat Rev Immunol 3 10 822 9 1:CAS:528:DC%2BD3sXoslSgsbk%3D 14523388
23. MA Clark MA Jepson BH Hirst 2001 Exploiting M cells for drug and vaccine delivery Adv Drug Deliv Rev 50 1-2 81 106 1:CAS:528:DC%2BD3MXlsF2js7k%3D 11489335
24. CF Kuper PJ Koornstra DM Hameleers J Biewenga BJ Spit AM Duijvestijn, et al. 1992 The role of nasopharyngeal lymphoid tissue Immunol Today 13 6 219 24 1:CAS:528:DyaK38Xlt12ns7o%3D 1627250
25. SS Davis 2001 Nasal vaccines Adv Drug Deliv Rev 51 1-3 21 42 1:CAS:528:DC%2BD3MXmtV2ntLs%3D 11516777
26. L Illum SS Davis 2001 Nasal vaccination: a non-invasive vaccine delivery method that holds great promise for the future Adv Drug Deliv Rev 51 1-3 1 3 1:CAS:528:DC%2BD3MXmtV2ntL0%3D 11516775
27. M Vajdy B Baudner G Del Giudice D O'Hagan 2007 A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza Clin Immunol 123 2 166 75 1:CAS:528:DC%2BD2sXksV2ls78%3D 17349825
28. A Porgador HF Staats Y Itoh BL Kelsall 1998 Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue Infect Immun 66 12 5876 81 1:CAS:528:DyaK1cXnvVChu7g%3D 9826368
29. MR Neutra E Pringault JP Kraehenbuhl 1996 Antigen sampling across epithelial barriers and induction of mucosal immune responses Annu Rev Immunol 14 275 300 1:CAS:528:DyaK28XitlCgtLg%3D 8717516
30. AM Mowat 2003 Anatomical basis of tolerance and immunity to intestinal antigens Nat Rev Immunol 3 4 331 41 1:CAS:528:DC%2BD3sXisFWku7s%3D 12669023
31. AT Gewirtz JL Madara 2001 Periscope, up! Monitoring microbes in the intestine Nat Immunol 2 4 288 90 1:CAS:528:DC%2BD3MXis1aktL0%3D 11276197
32. T Shikina T Hiroi K Iwatani MH Jang S Fukuyama M Tamura, et al. 2004 IgA class switch occurs in the organized nasopharynx- and gut-associated lymphoid tissue, but not in the diffuse lamina propria of airways and gut J Immunol 172 10 6259 64 1:CAS:528:DC%2BD2cXjs1Oju7c%3D 15128814
33. BC Baudner M Morandi MM Giuliani JC Verhoef HE Junginger P Costantino, et al. 2004 Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system J Infect Dis 189 5 828 32 1:CAS:528:DC%2BD2cXivFant7k%3D 14976599
34. V Snoeck IR Peters E Cox 2006 The IgA system: a comparison of structure and function in different species Vet Res 37 3 455 67 1:CAS:528: DC%2BD28Xls1Srtrk%3D 16611558
35. ME Lamm 1997 Interaction of antigens and antibodies at mucosal surfaces Annu Rev Microbiol 51 311 40 1:CAS:528:DyaK2sXms1Shtr4%3D 9343353
36. AB Hutchings A Helander KJ Silvey K Chandran WT Lucas ML Nibert, et al. 2004 Secretory immunoglobulin A antibodies against the sigma1 outer capsid protein of reovirus type 1 Lang prevent infection of mouse Peyer's patches J Virol 78 2 947 57 1:CAS:528:DC%2BD2cXjvFehsw%3D%3D 14694126
37. MF Kagnoff L Eckmann 1997 Epithelial cells as sensors for microbial infection J Clin Invest 100 1 6 10 1:CAS:528:DyaK2sXksVCmsrs%3D 9202050
38. AJ Macpherson NL Harris 2004 Interactions between commensal intestinal bacteria and the immune system Nat Rev Immunol 4 6 478 85 1:CAS:528: DC%2BD2cXksVaqsb0%3D 15173836
39. C Nagler-Anderson HN Shi 2001 Peripheral nonresponsiveness to orally administered soluble protein antigens Crit Rev Immunol 21 1-3 121 31 1:CAS:528:DC%2BD3MXnvVCrur4%3D 11642599
40. C Nagler-Anderson 2001 Man the barrier! Strategic defences in the intestinal mucosa Nat Rev Immunol 1 1 59 67 1:CAS:528:DC%2BD38XlvF2qtLc%3D 11905815
41. L Mayer L Shao 2004 Therapeutic potential of oral tolerance Nat Rev Immunol 4 6 407 19 1:CAS:528:DC%2BD2cXksVaqsb4%3D 15173830
42. M Rescigno M Urbano B Valzasina M Francolini G Rotta R Bonasio, et al. 2001 Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria Nat Immunol 2 4 361 7 1:CAS:528:DC%2BD3MXis1aktbo%3D 11276208
43. JL Viney AM Mowat JM O'Malley E Williamson NA Fanger 1998 Expanding dendritic cells in vivo enhances the induction of oral tolerance J Immunol 160 12 5815 25 1:CAS:528:DyaK1cXjvVWrsLo%3D 9637492
44. C Scheinecker R McHugh EM Shevach RN Germain 2002 Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node J Exp Med 196 8 1079 90 1:CAS:528:DC%2BD38XotFGltbo%3D 12391019
45. D Kunkel D Kirchhoff S Nishikawa A Radbruch A Scheffold 2003 Visualization of peptide presentation following oral application of antigen in normal and Peyer's patches-deficient mice Eur J Immunol 33 5 1292 301 1:CAS:528:DC%2BD3sXjvFyjsrY%3D 12731054
46. TW Spahn A Fontana AM Faria AJ Slavin HP Eugster X Zhang, et al. 2001 Induction of oral tolerance to cellular immune responses in the absence of Peyer's patches Eur J Immunol 31 4 1278 87 1:CAS:528:DC%2BD3MXivFyjsLs%3D 11298355
47. RE Mebius G Kraal 2005 Structure and function of the spleen Nat Rev Immunol 5 8 606 16 1:CAS:528:DC%2BD2MXmvVClsb4%3D 16056254
48. L Stertman E Lundgren I Sjoholm 2006 Starch microparticles as a vaccine adjuvant: only uptake in Peyer's patches decides the profile of the immune response Vaccine 24 17 3661 8 1:CAS:528:DC%2BD28XjtFGksb4%3D 16513226
49. YY Zuo H Alolabi A Shafiei N Kang Z Policova PN Cox, et al. 2006 Chitosan enhances the in vitro surface activity of dilute lung surfactant preparations and resists albumin-induced inactivation Pediatr Res 60 2 125 30 1:CAS:528:DC%2BD28XntFaksLk%3D 16864690
50. O'Hagan D. Microparticles as vaccine delivery systems. In: Schijins V, O'Hagan, D., editors. Immunopotentiators in modern vaccines, 1st ed. Academic; 2006. p. 123-47.
51. B Hansen A Sokolovska H HogenEsch SL Hem 2007 Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response Vaccine 25 36 6618 24 1:CAS:528:DC%2BD2sXovFKgtbs%3D 17681647
52. SL Hem H Hogenesch 2007 Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation Expert Rev Vaccines 6 5 685 98 1:CAS:528:DC%2BD2sXhtFGgsr3N 17931150
53. RK Gupta BE Rost E Relyveld GR Siber 1995 Adjuvant properties of aluminum and calcium compounds Pharm Biotechnol 6 229 48 1:CAS:528:DyaK2MXpsFGku78%3D 7551219
54. P Patel AM Salapatek 2006 Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine Expert Rev Vaccines 5 5 617 29 1:CAS:528:DC%2BD2sXnt1WgsQ%3D%3D 17181436
55. S Sharma TK Mukkur HA Benson Y Chen 2009 Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems J Pharm Sci 98 3 812 43 1:CAS:528:DC%2BD1MXjt1WlsbY%3D 18661544
56. FR Vogel C Caillet IC Kusters J Haensler 2009 Emulsion-based adjuvants for influenza vaccines Expert Rev Vaccines 8 4 483 92 1:CAS:528: DC%2BD1MXktFCiu78%3D 19348563
57. M Singh A Chakrapani D O'Hagan 2007 Nanoparticles and microparticles as vaccine-delivery systems Expert Rev Vaccines 6 5 797 808 1:CAS:528: DC%2BD2sXhtFGgsrzF 17931159
58. HX Sun Y Xie YP Ye 2009 ISCOMs and ISCOMATRIX Vaccine 27 33 4388 401 1:CAS:528:DC%2BD1MXotFCrtrw%3D 19450632
59. C Moser M Amacker AR Kammer S Rasi N Westerfeld R Zurbriggen 2007 Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations Expert Rev Vaccines 6 5 711 21 1:CAS:528:DC%2BD2sXhtFGgsrrP 17931152
60. JB McLachlan CP Shelburne JP Hart SV Pizzo R Goyal R Brooking-Dixon, et al. 2008 Mast cell activators: a new class of highly effective vaccine adjuvants Nat Med 14 5 536 41 1:CAS:528:DC%2BD1cXlsFCms78%3D 18425129
61. M Dupuis K Denis-Mize A LaBarbara W Peters IF Charo DM McDonald, et al. 2001 Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis Eur J Immunol 31 10 2910 8 1:CAS:528:DC%2BD3MXnvFSgt7Y%3D 11592066
62. IM van der Lubben G Kersten MM Fretz C Beuvery J Coos Verhoef HE Junginger 2003 Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice Vaccine 21 13-14 1400 8 12615436
63. MJ Pearse D Drane 2005 ISCOMATRIX adjuvant for antigen delivery Adv Drug Deliv Rev 57 3 465 74 1:CAS:528:DC%2BD2cXhtVSntbrK 15560952
64. JD Almeida DC Edwards CM Brand TD Heath 1975 Formation of virosomes from influenza subunits and liposomes Lancet 2 7941 899 901 1:STN:280: DyaE28%2FnsVWrtQ%3D%3D 53375
65. DT O'Hagan 1998 Microparticles and polymers for the mucosal delivery of vaccines Adv Drug Deliv Rev 34 2-3 305 20 10837683
66. DT O'Hagan M Singh 2003 Microparticles as vaccine adjuvants and delivery systems Expert Rev Vaccines 2 2 269 83 12899577
67. DT O'Hagan M Singh JB Ulmer 2004 Microparticles for the delivery of DNA vaccines Immunol Rev 199 191 200 15233735
68. T Storni TM Kundig G Senti P Johansen 2005 Immunity in response to particulate antigen-delivery systems Adv Drug Deliv Rev 57 3 333 55 1:CAS:528:DC%2BD2cXhtVSntb3F 15560945
69. H Tamber P Johansen HP Merkle B Gander 2005 Formulation aspects of biodegradable polymeric microspheres for antigen delivery Adv Drug Deliv Rev 57 3 357 76 1:CAS:528:DC%2BD2cXhtVSntbrM 15560946
70. S Jilek HP Merkle E Walter 2005 DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells Adv Drug Deliv Rev 57 3 377 90 1:CAS:528:DC%2BD2cXhtVSntbrN 15560947
71. Y Waeckerle-Men M Groettrup 2005 PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines Adv Drug Deliv Rev 57 3 475 82 1:CAS:528:DC%2BD2cXhtVSntbrL 15560953
72. DT O'Hagan NM Valiante 2003 Recent advances in the discovery and delivery of vaccine adjuvants Nat Rev Drug Discov 2 9 727 35 12951579
73. AT Florence 1997 The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual Pharm Res 14 3 259 66 1:CAS:528: DyaK2sXisVGlsro%3D 9098866
74. N Hussain V Jaitley AT Florence 2001 Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics Adv Drug Deliv Rev 50 1-2 107 42 1:CAS:528:DC%2BD3MXlsF2js7Y%3D 11489336
75. T Jung W Kamm A Breitenbach E Kaiserling JX Xiao T Kissel 2000 Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm 50 1 147 60 1:CAS:528:DC%2BD3cXjslyisrs%3D 10840198
76. MJ Cano-Cebrian T Zornoza L Granero A Polache 2005 Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery Curr Drug Deliv 2 1 9 22 1:CAS:528: DC%2BD2MXhvFWktw%3D%3D 16305404
77. M Aprahamian C Michel W Humbert JP Devissaguet C Damge 1987 Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine Biol Cell 61 1-2 69 76 1:CAS:528:DyaL1cXhsFKgtL0%3D 2833966
78. TT MacDonald 2003 The mucosal immune system Parasite Immunol 25 5 235 46 1:CAS:528:DC%2BD3sXos1Clur8%3D 12969442
79. I Jabbal-Gill W Lin P Jenkins P Watts M Jimenez L Illum, et al. 1999 Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines Vaccine 18 3-4 238 50 1:CAS:528:DyaK1MXnsVegtb0%3D 10506648
80. A Delgado EC Lavelle M Hartshorne SS Davis 1999 PLG microparticles stabilised using enteric coating polymers as oral vaccine delivery systems Vaccine 17 22 2927 38 1:CAS:528:DyaK1MXltVWrtr4%3D 10438065
81. M Manocha PC Pal KT Chitralekha BE Thomas V Tripathi SD Gupta, et al. 2005 Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target Vaccine 23 48-49 5599 617 1:CAS:528:DC%2BD2MXht1ars7fI 16099080
82. R Rajkannan MD Dhanaraju D Gopinath D Selvaraj R Jayakumar 2006 Development of hepatitis B oral vaccine using B-cell epitope loaded PLG microparticles Vaccine 24 24 5149 57 1:CAS:528:DC%2BD28Xltlems74%3D 16713035
83. AC Stanley D Buxton EA Innes JF Huntley 2004 Intranasal immunisation with Toxoplasma gondii tachyzoite antigen encapsulated into PLG microspheres induces humoral and cell-mediated immunity in sheep Vaccine 22 29-30 3929 41 1:CAS:528:DC%2BD2cXnsFGns7w%3D 15364441
84. M Wu L Shi S Liu J Li K Wu L Wang, et al. 2005 The effect of entrapment of CpG sequence with cationic PLG nanoparticles on the immune responses of mice to pig paratyphoid vaccine Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 22 5 975 9 1:CAS:528:DC%2BD28XpsFOnt7c%3D 16294734
85. MK Yeh AG Coombes JL Chen CH Chiang 2002 Japanese encephalitis virus vaccine formulations using PLA lamellar and PLG microparticles J Microencapsul 19 5 671 82 1:CAS:528:DC%2BD38Xotlaisrs%3D 12433308
86. AJ Almeida HO Alpar MR Brown 1993 Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(L-lactic acid) microspheres in rats, rabbits and guinea-pigs J Pharm Pharmacol 45 3 198 203 1:CAS:528:DyaK3sXisVSkur4%3D 8097777
87. RK Gupta M Singh DT O'Hagan 1998 Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines Adv Drug Deliv Rev 32 3 225 46 10837646
88. J Chesko J Kazzaz M Ugozzoli T, Singh M. An investigation of the factors controlling the adsorption of protein antigens to anionic PLG microparticles J Pharm Sci 94 11 2510 9 1:CAS:528:DC%2BD2MXht1OgtbfF 16200615
89. HJ Mollenkopf G Dietrich J Fensterle L Grode KD Diehl B Knapp, et al. 2004 Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles Vaccine 22 21-22 2690 5 1:CAS:528: DC%2BD2cXls1Wktr8%3D 15309815
90. B Kim T Bowersock P Griebel A Kidane LA Babiuk M Sanchez, et al. 2002 Mucosal immune responses following oral immunization with rotavirus antigens encapsulated in alginate microspheres J Control Release 85 1-3 191 202 1:CAS:528:DC%2BD38Xpt12ksL4%3D 12480324 (Pubitemid 35452637)
91. L Strindelius L Degling Wikingsson I Sjoholm 2002 Extracellular antigens from Salmonella enteritidis induce effective immune response in mice after oral vaccination Infect Immun 70 3 1434 42 1:CAS:528:DC%2BD38XhsFSlsbg%3D 11854230
92. Holmgren J, Harandi A, Lebens M, Sun J-B, Anjuère F, Czerkinsky C. Mucosal adjuvants based on cholera toxin and E. coli heat-labile enterotoxin. In: Schijns V, O'Hagan, D., editors. Immunopotentiators in modern vaccines, 1st ed. Academic; 2006. p. 235-52.
93. G Douce M Fontana M Pizza R Rappuoli G Dougan 1997 Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin Infect Immun 65 7 2821 8 1:CAS:528:DyaK2sXktVyls78%3D 9199455
94. G Douce C Turcotte I Cropley M Roberts M Pizza M Domenghini, et al. 1995 Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants Proc Natl Acad Sci U S A 92 5 1644 8 1:CAS:528:DyaK2MXktFWrsr0%3D 7878032
95. K Fujihashi T Koga FW van Ginkel Y Hagiwara JR McGhee 2002 A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants Vaccine 20 19-20 2431 8 1:CAS:528:DC%2BD38XktFKhs7w%3D 12057597
96. MM Levine 2000 Immunization against bacterial diseases of the intestine J Pediatr Gastroenterol Nutr 31 4 336 55 1:CAS:528:DC%2BD3cXnsFCqur4%3D 11045827
97. NV Malkevitch M Robert-Guroff 2004 A call for replicating vector prime-protein boost strategies in HIV vaccine design Expert Rev Vaccines 3 4 Suppl S105 17 15285710
98. E Cox F Verdonck D Vanrompay B Goddeeris 2006 Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa Vet Res 37 3 511 39 1:CAS:528:DC%2BD28Xls1Srt74%3D 16611561
99. McCluskie MJ, Weeratna RD. CpG oligodeoxynucleotides as vaccine adjuvants. In: Schijins V, O'Hagan D., editors. Immunopotentiators in modern vaccines, 1st ed. Academic; 2006. p. 73-92.
100. SJ McSorley BD Ehst Y Yu AT Gewirtz 2002 Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo J Immunol 169 7 3914 9 1:CAS:528:DC%2BD38XnsFeltb0%3D 12244190
101. S Chabot A Brewer G Lowell M Plante S Cyr DS Burt, et al. 2005 A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice Vaccine 23 11 1374 83 1:CAS:528:DC%2BD2MXmslGguw%3D%3D 15661386
102. CL Cooper HL Davis JB Angel ML Morris SM Elfer I Seguin, et al. 2005 CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults Aids 19 14 1473 9 1:CAS:528:DC%2BD2MXpsFynurY%3D 16135900
103. CL Cooper HL Davis ML Morris SM Efler MA Adhami AM Krieg, et al. 2004 CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study J Clin Immunol 24 6 693 701 1:CAS:528:DC%2BD2MXhtFSmsQ%3D%3D 15622454
104. AM Krieg AK Yi S Matson TJ Waldschmidt GA Bishop R Teasdale, et al. 1995 CpG motifs in bacterial DNA trigger direct B-cell activation Nature 374 6522 546 9 1:CAS:528:DyaK2MXkvVKqtr8%3D 7700380
105. P Ahmad-Nejad H Hacker M Rutz S Bauer RM Vabulas H Wagner 2002 Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments Eur J Immunol 32 7 1958 68 1:CAS:528:DC%2BD38XlsFajurg%3D 12115616
106. WS Gallichan RN Woolstencroft T Guarasci MJ McCluskie HL Davis KL Rosenthal 2001 Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract J Immunol 166 5 3451 7 1:CAS:528: DC%2BD3MXhs1Ois7s%3D 11207303
107. MJ McCluskie HL Davis 1998 CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice J Immunol 161 9 4463 6 1:CAS:528:DyaK1cXntVWhurg%3D 9794366
108. MJ McCluskie HL Davis 2000 Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants Vaccine 19 4-5 413 22 1:CAS:528:DC%2BD3cXntF2ku70%3D 11027803
109. A Kwant KL Rosenthal 2004 Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2 Vaccine 22 23-24 3098 104 1:CAS:528:DC%2BD2cXmsVCqt7w%3D 15297061
110. JW Eastcott CJ Holmberg FE Dewhirst TR Esch DJ Smith MA Taubman 2001 Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid Vaccine 19 13-14 1636 42 1:CAS:528:DC%2BD3MXptVylsQ%3D%3D 11166886
111. MJ McCluskie RD Weeratna AM Krieg HL Davis 2000 CpG DNA is an effective oral adjuvant to protein antigens in mice Vaccine 19 7-8 950 7 1:CAS:528:DC%2BD3cXoslCktrk%3D 11115721
112. MJ McCluskie RD Weeratna PJ Payette HL Davis 2002 Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA FEMS Immunol Med Microbiol 32 3 179 85 1:CAS:528:DC%2BD38XisV2mu7Y%3D 11934561
113. RD Weeratna CL Brazolot Millan MJ McCluskie HL Davis 2001 CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice FEMS Immunol Med Microbiol 32 1 65 71 1:CAS:528:DC%2BD3MXpt1amt70%3D 11750224
114. R Schwandner R Dziarski H Wesche M Rothe CJ Kirschning 1999 Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2 J Biol Chem 274 25 17406 9 1:CAS:528:DyaK1MXktVymt7Y%3D 10364168
115. A Yoshimura E Lien RR Ingalls E Tuomanen R Dziarski D Golenbock 1999 Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2 J Immunol 163 1 1 5 1:CAS:528:DyaK1MXktF2rsLc%3D 10384090
116. L Alexopoulou AC Holt R Medzhitov RA Flavell 2001 Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3 Nature 413 6857 732 8 1:CAS:528:DC%2BD3MXnvFegsL0%3D 11607032
117. H An Y Yu M Zhang H Xu R Qi X Yan, et al. 2002 Involvement of ERK, p38 and NF-kappaB signal transduction in regulation of TLR2, TLR4 and TLR9 gene expression induced by lipopolysaccharide in mouse dendritic cells Immunology 106 1 38 45 1:CAS:528:DC%2BD38XjvVGgtbc%3D 11972630
118. JC Chow DW Young DT Golenbock WJ Christ F Gusovsky 1999 Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction J Biol Chem 274 16 10689 92 1:CAS:528:DyaK1MXis1Gntbw%3D 10196138
119. E Lien TK Means H Heine A Yoshimura S Kusumoto K Fukase, et al. 2000 Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide J Clin Invest 105 4 497 504 1:CAS:528:DC%2BD3cXhtlygu7c%3D 10683379
120. SH Rhee D Hwang 2000 Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF kappa B and expression of the inducible cyclooxygenase J Biol Chem 275 44 34035 40 1:CAS:528:DC%2BD3cXotFWmurw%3D 10952994
121. F Hayashi KD Smith A Ozinsky TR Hawn EC Yi DR Goodlett, et al. 2001 The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5 Nature 410 6832 1099 103 1:CAS:528:DC%2BD3MXjsVCrsbo%3D 11323673
122. AT Gewirtz TA Navas S Lyons PJ Godowski JL Madara 2001 Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression J Immunol 167 4 1882 5 1:CAS:528: DC%2BD3MXlvFeqt7Y%3D 11489966
123. F Heil H Hemmi H Hochrein F Ampenberger C Kirschning S Akira, et al. 2004 Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8 Science 303 5663 1526 9 1:CAS:528:DC%2BD2cXhslCgsLc%3D 14976262
124. H Hemmi O Takeuchi T Kawai T Kaisho S Sato H Sanjo, et al. 2000 A Toll-like receptor recognizes bacterial DNA Nature 408 6813 740 5 1:CAS:528:DC%2BD3cXptVCqsL0%3D 11130078
125. A Krug A Towarowski S Britsch S Rothenfusser V Hornung R Bals, et al. 2001 Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12 Eur J Immunol 31 10 3026 37 1:CAS:528: DC%2BD3MXnvFSgtb8%3D 11592079 (Pubitemid 32994554)
126. F Takeshita CA Leifer I Gursel KJ Ishii S Takeshita M Gursel, et al. 2001 Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells J Immunol 167 7 3555 8 1:CAS:528:DC%2BD3MXntFajs7s%3D 11564765